Lyon-based Brenus Pharma secures 22.2M to advance cancer vaccine trials: Here's how - Silicon Canals
Brenus Pharma secures €22.2M Series A funding to advance cancer vaccine development, targeting metastatic colorectal cancer and expanding into other gastric tumors.